ALCHEMIA’S SYNTHETIC HEPARIN DELAYED; PATENTS GRANTED
June 24th 2008 00:09
Monday June 23, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: UNIVERSAL BIO UP 5%, BENITEC DOWN 11%
* ALCHEMIA’S SYNTHETIC HEPARIN DELAYED; PATENTS GRANTED
* NOVOGEN LICENCES ISOFLAVONOID PATENT TO SPANISH FLEET
* SHAREHOLDERS CALL FOR APOLLO BOARD SPILL
* SAFETY MEDICAL DEVELOPS NEEDLE-CAP HOLDER
* COMPUMEDICS’ CHAIRMAN TO SELL DOWN; REALIZE VALUE
* ELLEX REQUESTS PERSONNEL CHANGES TRADING HALT
* NORWOOD PLACEMENT RAISES $200k
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
ALCHEMIA
Alchemia’s synthetic heparin launch has been delayed by up to six months.
Alchemia chief executive officer Dr Pete Smith told Biotech Daily that the launch had been “delayed by up to six months due to the time taken to overcome a range of minor technical issues”.
In a media release to the market Alchemia said that with its manufacturing partner Dr Reddy’s of India it had “made significant progress towards commercialization”, with approval and launch expected by June 30, 2009 depending on review time at the US Food and Drug Administration.
Alchemia also said it had been granted the first two Australian patents in the ‘synthetic heparin oligosaccharide’ family of patents.
Two more divisional applications have completed the examination process, have been accepted and “are expected to be sealed in the next few months”.
The patents are being examined in other major markets.
Alchemia’s vice-president of intellectual property Michael West said the patent family provided legal protection for Alchemia’s processes for the synthesis of fondaparinux sodium through to September 6, 2022.
There has been an increased interest in synthetic heparin following a contamination scare involving animal-derived heparin earlier this year (see Biotech Daily; March 25, 2008).
Alchemia’s fondaparinux is free of animal products.
Alchemia climbed 1.5 cents or 4.41 percent to 35.5 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 37 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
